#AGL

A highly relevant topic for #AGL at this upcoming Liquid Biopsy Symposium. Several panelists are very ‘familiar’ with Parsortix. For example, Carolina Reduzzi recently contributed to HER2 research presented at SABCS. Massimo Cristofanilli played a key role in the study that

Avacta have 3 6k indications that could be P2 ready within 6 months. Can they partner one of them and generate enough cash to run the other two themselves ? One is small and straightforward, one a bit bigger but complex, the third is huge. So, how do they cut it ? #avct

Sandy Radford @Wednesday123440 Myles McNulty Simøn West RAH Cumulus Exciting to think how trials/therapy might incorporate such data. e.g. I show up at Dr with cancer (any indication). I'm i) imaged to determine FAP levels ii) sequenced to determine gene (e.g. SLF11N) expression. If high-high, then whatever indication, I'm treated with AVA6103

#AVCT CC outlined the financial strategy at last year’s AGM. It’s worth a revisit re their short term non-dilutive objectives: “…we have two-non dilutive capital sources in the short term that we will be looking at. The first is to realize the value for our diagnostics assets

Delighted to see Richard Hughes join the board. Avacta has long needed sharper commercial execution. His appointment is a clear step towards turning scientific promise into shareholder value. #AVCT

Now focus has returned to the excellent progress pre|CISION continues to make in clinic, TVR5 looks forward to the FAP-Dox data being presented at #ESMO25 in Berlin. A strengthened commercial team to support #AVCT’s next chapter.

The appointment of Zeus as joint broker and strengthened commercial board continues to deliver tangible value for #AVCT shareholders. TVR5 thanks Richard Hughes for continuing to prioritise the restoration of shareholder value as Avacta enters an exciting period for FAP-Dox.

Today’s deferment of the loan note protects shareholders and restores value; allowing #AVCT to focus on the advancement of preCISION. TVR5 would like to see Richard Hughes move into an executive position. His track record of protecting shareholders is clear. #Hughes4Chair

#AVCT board admitted they couldn’t fix the toxic debt (CLN) after 3 yrs. New NED Richard Hughes has succeeded where others failed. Cracking it in months. Pre|CISION just did the same in clinic with FAP. #Hughes4Chair - It works.

Tony Fawcett Richard Hughes Well said, couldn’t agree more #Hughes4Chair

At the April data cut-off in the FAP-Dox phase 1a SGC cohort, #AVCT had nearly doubled the benchmark PFS median to 5.9 months. “Because we haven’t reached median yet, this number can only get better.” (Chris, AACR review) At the most recent R&D Spotlight, Chris said: “AVA6000 is

Avacta’s pre|CISION platform progresses:  ·      AVA6000 Phase 1b shows early activity, Phase 1a data to be presented at ESMO 2025  ·      AVA6103 on track for 1st patient Q1 2026  ·      Multiple updates due Q4 2025  ·      Active BD discussions signal growing partner

"Avacta is in a very strong position... everything is going according to plan... I think that the future is very bright for this company. It is very bright...What Avacta has been able to accomplish here is truly remarkable... And I'll say it again, the future is VERY BRIGHT for

My thanks also to B2HS2L for sharing this AI-generated #AVCT Investor Meet podcast on LSE yesterday. As others have mentioned, it highlights a key point - exatecan is so potent it can even overcome resistance to another Topo-1 chemotherapy.